SG11201503051QA - Formulations of pyrimidinedione derivative compounds - Google Patents

Formulations of pyrimidinedione derivative compounds

Info

Publication number
SG11201503051QA
SG11201503051QA SG11201503051QA SG11201503051QA SG11201503051QA SG 11201503051Q A SG11201503051Q A SG 11201503051QA SG 11201503051Q A SG11201503051Q A SG 11201503051QA SG 11201503051Q A SG11201503051Q A SG 11201503051QA SG 11201503051Q A SG11201503051Q A SG 11201503051QA
Authority
SG
Singapore
Prior art keywords
formulations
derivative compounds
pyrimidinedione derivative
pyrimidinedione
compounds
Prior art date
Application number
SG11201503051QA
Other languages
English (en)
Inventor
Yanxia Li
Ping Gao
Yi Shi
Hao Hou
Michael Mackaplow
Kelley A Meadows
Geoff G Zhang
Yi Gao
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of SG11201503051QA publication Critical patent/SG11201503051QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201503051QA 2012-10-18 2013-10-18 Formulations of pyrimidinedione derivative compounds SG11201503051QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261715766P 2012-10-18 2012-10-18
PCT/US2013/065760 WO2014063101A1 (en) 2012-10-18 2013-10-18 Formulations of pyrimidinedione derivative compounds

Publications (1)

Publication Number Publication Date
SG11201503051QA true SG11201503051QA (en) 2015-05-28

Family

ID=49554481

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201503051QA SG11201503051QA (en) 2012-10-18 2013-10-18 Formulations of pyrimidinedione derivative compounds

Country Status (11)

Country Link
US (2) US9629841B2 (enrdf_load_stackoverflow)
EP (1) EP2908808A1 (enrdf_load_stackoverflow)
JP (2) JP6266635B2 (enrdf_load_stackoverflow)
CN (2) CN109260207A (enrdf_load_stackoverflow)
AU (1) AU2013330993B2 (enrdf_load_stackoverflow)
BR (1) BR112015008927A2 (enrdf_load_stackoverflow)
CA (1) CA2888883A1 (enrdf_load_stackoverflow)
EA (2) EA028481B1 (enrdf_load_stackoverflow)
MX (1) MX2015004973A (enrdf_load_stackoverflow)
SG (1) SG11201503051QA (enrdf_load_stackoverflow)
WO (1) WO2014063101A1 (enrdf_load_stackoverflow)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
CN115605186A (zh) * 2020-03-05 2023-01-13 奥瑞基尼探索技术有限公司（In） 激酶抑制剂的药物组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4442257A1 (de) * 1994-11-28 1996-05-30 Beate Dr Podschun Sparsomycin
HUP0102206A3 (en) 1998-06-11 2002-12-28 Upjohn Co Delavirdine tablet formulation
PL357470A1 (en) 1999-12-23 2004-07-26 Pfizer Products Inc. Pharmaceutical compositions providing enhanced drug concentrations
GB0009522D0 (en) * 2000-04-19 2000-06-07 Smithkline Beecham Plc Composition
US6489363B2 (en) * 2000-10-11 2002-12-03 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
WO2006066063A1 (en) * 2004-12-15 2006-06-22 Elan Pharma International Ltd. Nanoparticulate tacrolimus formulations
WO2007044574A2 (en) * 2005-10-06 2007-04-19 Transtech Pharma, Inc. Pharmaceutical compositions, methods of preparation thereof, and methods of treatment
ES2453591T3 (es) * 2007-09-17 2014-04-08 Abbvie Bahamas Ltd. Derivado de uracilo o timina para el tratamiento de la hepatitis C
US8188104B2 (en) * 2007-09-17 2012-05-29 Abbott Laboratories Anti-infective agents and uses thereof
US20100166861A1 (en) * 2008-12-29 2010-07-01 Kelly Noel Lynch Pharmaceutical formulations of sevalamer, or salts thereof, and copovidone
EP2542075A4 (en) * 2010-03-01 2014-11-05 Concert Pharmaceuticals Inc Fluorouracil DERIVATIVES
DE202012012954U1 (de) * 2011-10-21 2014-08-12 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV

Also Published As

Publication number Publication date
CN104853752B (zh) 2018-10-23
CN104853752A (zh) 2015-08-19
EA201590752A1 (ru) 2016-02-29
JP2018065858A (ja) 2018-04-26
MX2015004973A (es) 2015-07-17
US10201542B2 (en) 2019-02-12
EA028481B1 (ru) 2017-11-30
CA2888883A1 (en) 2014-04-24
JP2015534985A (ja) 2015-12-07
AU2013330993A1 (en) 2015-05-07
AU2013330993B2 (en) 2018-03-01
US9629841B2 (en) 2017-04-25
US20170181973A1 (en) 2017-06-29
CN109260207A (zh) 2019-01-25
US20140113921A1 (en) 2014-04-24
EA201791354A2 (ru) 2017-11-30
EA201791354A3 (ru) 2018-03-30
EA032913B1 (ru) 2019-08-30
EP2908808A1 (en) 2015-08-26
JP6266635B2 (ja) 2018-01-24
BR112015008927A2 (pt) 2017-07-04
WO2014063101A1 (en) 2014-04-24

Similar Documents

Publication Publication Date Title
IL277652B (en) Stable aqueous formulations of adlimumab
ZA201501847B (en) Formulations of enzalutamide
HUE064884T2 (hu) Bendamusztin kiszerelések
PL4082524T3 (pl) Preparaty triazynowe
PL2908835T3 (pl) Stabilne formulacje
ZA201500290B (en) Crystalline forms of dihydropyrimidine derivatives
SG11201503051QA (en) Formulations of pyrimidinedione derivative compounds
ZA201502350B (en) Solid form of hihydro-pyrido-oxazine derivative
HK40116766A (en) Formulations of enzalutamide
HK40108713A (en) Formulations of enzalutamide
HK40109505A (zh) 苯達莫司汀的製劑
SI2928896T1 (sl) Trdna oblika derivata dihidro-pirido-oksazina
IL234771A0 (en) Nicotine formulation
GB201206178D0 (en) Formulations